Pricing Log in Create free account

Alumis Inc. (ALMS) vs Rigel Pharmaceuticals, Inc. (RIGL)

Alumis Inc. and Rigel Pharmaceuticals, Inc. are both Biotechnology companies. Alumis Inc. and Rigel Pharmaceuticals, Inc. are of similar size ($883.7M and $838.3M). Alumis Inc. has negative trailing earnings, so its P/E is not meaningful; Rigel Pharmaceuticals, Inc. trades at 2.6×. Rigel Pharmaceuticals, Inc. has the higher net margin (106.6% vs −5,933.5%) and the higher return on invested capital (13.7% vs 0.00%). Across the 15 metrics below, Rigel Pharmaceuticals, Inc. leads on 13 and Alumis Inc. on 2.

Valuation

Metric ALMS RIGL Biotechnology median
P/E n/m 2.64 11.58
P/S 114.26 2.88 9.61
P/B 1.87 1.87 2.26
Price to free cash flow n/m 42.58 26.41
EV/EBITDA n/m 9.44 0.72
EV/Sales 46.37 2.59 9.43
Earnings yield (57.29%) 37.87% (32.28%)
Free cash flow yield (41.62%) 2.35% (22.27%)

Profitability

Metric ALMS RIGL Biotechnology median
Gross margin 100.00% 89.64% 68.81%
Operating margin (6,204.39%) 26.28% 0.00%
Net margin (5,933.45%) 106.59% 0.00%
Free cash flow margin (4,755.33%) 6.72% 0.00%
Return on equity (93.65%) 109.18% (50.30%)
Return on assets (74.94%) 80.16% (45.47%)
Return on invested capital 0.00% 13.69% 0.00%

Growth

Metric ALMS RIGL Biotechnology median
Revenue growth (TTM) — 2.18% 6.78%
EPS growth (last fiscal year) 72.45% 1,867.68% 29.88%
Revenue growth, 5-year CAGR — 22.06% 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric ALMS RIGL Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 6.74 2.39 4.74
Net debt to EBITDA 0.69 (1.05) 1.01

Dividend

Metric ALMS RIGL Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric ALMS RIGL Biotechnology median
Market cap 883.74m 838.31m 168.63m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack